Syros Pharmaceuticals is a biopharmaceutical company based in Cambridge, MA, dedicated to improving the lives of cancer patients through the development of novel gene control medicines. They focus on identifying cancer patients with abnormal gene expression and developing targeted therapies to address hematologic malignancies. With a mission to make a profound difference in the lives of patients and their families, Syros is advancing their late-stage clinical pipeline to provide new treatment options for blood disorders that have been difficult to treat with current approaches.
By controlling gene expression with small molecule therapies, Syros aims to address diseases caused by alterations in regulatory regions of the genome. Their gene control platform has led to the discovery of several targets for small molecule drugs, with a particular focus on cancers that have not been effectively treated by other genomics-based approaches. With a collaborative and patient-driven culture, Syros is committed to transforming lives through innovative science and breakthrough treatments.
Generated from the website